More than 110,000 Hoosiers suffer from Alzheimer’s disease, which robs people of their memories and abilities to do daily tasks, and is the nation’s sixth-leading cause of death.
Patty Martin joined BioCrossroads as president and CEO in July 2019. She stepped down from the role in April. She previously worked as chief operating officer of Lilly Diabetes and served as Eli Lilly and Co.’s chief diversity officer and chief alliance officer. She is a member of the Indiana University Foundation and Women’s Philanthropy […]
If U.S. regulators approve, the drug would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease—after rival Leqembi. Both drugs pose a serious safety concern—brain swelling and bleeding.
His departure comes as his two-year contract with the state expires, but it still increases speculation that he is considering a run for governor in 2024.
She first gained public notice as a piano soloist with the Indianapolis Symphony Orchestra at age 12. She later endured the tragic deaths of both her father and her husband Frank McKinney Jr. in separate airplane crashes.
The list, available at Indiana250.com, was compiled by the executives, editors and newsroom staffs at IBJ Media’s three news brands — Indianapolis Business Journal, Inside INdiana Business and Indiana Lawyer — after a monthslong process that included reviewing nominations, researching Indiana organizations and talking with community leaders across the state.
The list includes a hospital executive who collects guitars but can’t play them, and a health insurance leader whose dream job is to become a professional sports coach.
Conner Prairie’s plan to expand the outdoor living-history museum west of the White River received a boost Tuesday night from the Carmel Plan Commission.
The Indiana Economic Development Corp. is seeking $120 million in performance-based incentive funds for a company planning a new facility that will create 1,400 high-wage jobs, according to the State Budget Committee’s agenda for its Friday meeting.
Indianapolis-based Eli Lilly and Co. and the maker of popular diabetes drug Ozempic are accused of failing to warn consumers and physicians about the risk of “severe gastrointestinal events” resulting from the use of two diabetes drugs.
The mystery project involves a company in the “advanced technology automotive components” industry and would be located somewhere in north-central Indiana, according to the IEDC.
The U.S. Food and Drug Administration gave the green light to MBX to test a drug for post-bariatric hypoglycemia, a rare disease and a serious complication of bariatric surgery, the company said Monday.
The Indianapolis-based pharmaceutical company’s first-quarter performance was driven by strong sales of leading drugs for diabetes, cancer and other diseases.
Paula Angarita Rivera is principal scientist for the bioproduct research and development organization at Eli Lilly and Co. In her role, she supports the development of test methods that generate data for the FDA approval of Lilly’s medical devices and the design of engineering studies to support the drug product manufacturing process.
Much of the excitement is due to strong results from Mounjaro, which hit the market in June 2022 as a treatment for Type 2 diabetes and rang up $979.7 million in the quarter.
